RJA
GBT

Raymond James & Associates’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Raymond James & Associates’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,373
Closed -$221K – 4287
2022
Q1 		$221K Sell
6,373
-562
-8% -$16.8K ﹤0.01% 3615
2021
Q4 		$203K Sell
6,935
-7,235
-51% -$224K ﹤0.01% 3697
2021
Q3 		$361K Buy
14,170
+6,150
+77% +$181K ﹤0.01% 3289
2021
Q2 		$281K Sell
8,020
-1,782
-18% -$69.6K ﹤0.01% 3482
2021
Q1 		$399K Sell
9,802
-1,420
-13% -$65.3K ﹤0.01% 3173
2020
Q4 		$486K Sell
11,222
-1,538
-12% -$75.8K ﹤0.01% 2827
2020
Q3 		$704K Sell
12,760
-6,886
-35% -$438K ﹤0.01% 2402
2020
Q2 		$1.24M Buy
19,646
+2,728
+16% +$187K ﹤0.01% 2016
2020
Q1 		$864K Sell
16,918
-4,845
-22% -$325K ﹤0.01% 2080
2019
Q4 		$1.73M Buy
21,763
+4,338
+25% +$257K ﹤0.01% 1908
2019
Q3 		$845K Buy
17,425
+8,211
+89% +$428K ﹤0.01% 2288
2019
Q2 		$485K Buy
+9,214
New +$529K ﹤0.01% 2691

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Raymond James & Associates's GBT Position: Q2 2022 in Review

Raymond James & Associates sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 6,373 shares — an estimated $221K sold.

Raymond James & Associates first reported a position in GBT in Q2 2019 and held it in 12 quarters. The position peaked at $1.73M in Q4 2019. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

  • Raymond James & Associates reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 6,373 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $221K.
  • Raymond James & Associates first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 12 quarters.
  • Raymond James & Associates's Global Blood Therapeutics, Inc. position peaked at $1.73M in Q4 2019.
  • 195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.